These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35649655)

  • 1. Imaging of Synaptic Density in Neurodegenerative Disorders.
    Carson RE; Naganawa M; Toyonaga T; Koohsari S; Yang Y; Chen MK; Matuskey D; Finnema SJ
    J Nucl Med; 2022 Jun; 63(Suppl 1):60S-67S. PubMed ID: 35649655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review.
    Visser M; O'Brien JT; Mak E
    Ageing Res Rev; 2024 Feb; 94():102197. PubMed ID: 38266660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
    J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of SV2A Binding in Rodent Brain Using [
    Sadasivam P; Fang XT; Toyonaga T; Lee S; Xu Y; Zheng MQ; Spurrier J; Huang Y; Strittmatter SM; Carson RE; Cai Z
    Mol Imaging Biol; 2021 Jun; 23(3):372-381. PubMed ID: 33258040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation, kinetic modeling, and test-retest reproducibility of [
    Bertoglio D; Zajicek F; Lombaerde S; Miranda A; Stroobants S; Wang Y; Dominguez C; Munoz-Sanjuan I; Bard J; Liu L; Verhaeghe J; Staelens S
    J Cereb Blood Flow Metab; 2022 Oct; 42(10):1867-1878. PubMed ID: 35570828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
    Kumar A; Scarpa M; Nordberg A
    Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SV2A PET imaging in human neurodegenerative diseases.
    Bavarsad MS; Grinberg LT
    Front Aging Neurosci; 2024; 16():1380561. PubMed ID: 38699560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vivo evaluation of [
    Li S; Cai Z; Zhang W; Holden D; Lin SF; Finnema SJ; Shirali A; Ropchan J; Carre S; Mercier J; Carson RE; Nabulsi N; Huang Y
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1952-1965. PubMed ID: 31175396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.